$22.5M
+$22.5M this year1 filing since 2026 · latest Equity filed
Pacegenix is a Cambridge, Massachusetts clinical-stage biotech developing precision cardiology therapeutics for cardiac rhythm disorders. Its pipeline consists of first-in-class prodrugs aimed at rhythm and rate control in patients underserved by existing antiarrhythmic drugs. Lead program PACE-101 targets atrial fibrillation in hypertrophic cardiomyopathy (AF-HCM), where standard antiarrhythmics are contraindicated or ineffective; PACE-201 targets inappropriate rapid heart rates including inappropriate sinus tachycardia and tachycardia in heart failure. The company was founded in 2024, incubated by Genesis BioCapital, and is led by CEO Jay Wohlgemuth, MD.
What sets it apart
Prodrug approach designed to control heart rhythm and rate in populations where current antiarrhythmics are contraindicated or compromise cardiac function, with PACE-101 aiming to be the first approved therapy for atrial fibrillation in hypertrophic cardiomyopathy.
A rhythm-control drug candidate targeting atrial fibrillation in patients with hypertrophic cardiomyopathy (AF-HCM).
